Literature DB >> 34712996

Co-staining human PBMCs with fluorescent antibodies and antibody-oligonucleotide conjugates for cell sorting prior to single-cell CITE-Seq.

Xiaoshan Shi1, Gisele V Baracho2, Woodrow E Lomas1, Stephanie J Widmann2, Aaron J Tyznik2.   

Abstract

The dual interrogation of the transcriptome and proteome with single-cell resolution provides exquisite insights into immune mechanisms in health and disease. Here, we describe a cutting-edge protocol wherein we combine Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-Seq), a technique utilizing antibody-oligonucleotide conjugates (AOCs), with fluorescence-activated cell sorting to enrich rare cell populations. Our protocol incorporates co-staining of cells with both fluorescent antibodies and AOCs simultaneously for subsequent input into the cell sorting and CITE-Seq pipeline. For complete details on the use and execution of this protocol, please refer to Mair et al. (2020).
© 2021 Becton, Dickenson and Company.

Entities:  

Keywords:  Antibody; Biotechnology and bioengineering; Cell isolation; Flow Cytometry/Mass Cytometry; Immunology; Molecular Biology; Single Cell

Mesh:

Substances:

Year:  2021        PMID: 34712996      PMCID: PMC8529558          DOI: 10.1016/j.xpro.2021.100893

Source DB:  PubMed          Journal:  STAR Protoc        ISSN: 2666-1667


Before you begin

Our protocol described herein are performed using fresh peripheral blood mononuclear cells (PBMCs) isolated from human whole blood. In this section, we provide a method for their isolation. Frozen PBMCs can also be used. Our co-staining protocol may also be suitable for co-staining other cell types from different species. Separately, we suggest preparing the appropriate reagents to be utilized in the assay in advance, as detailed below.

Prepare cells: Isolation of PBMCs from human whole blood using SepMateTM-50

Timing: 30 min Here, we present a method to isolate PBMCs from human whole blood using the SepMateTM-50 system (see product information sheet for detailed instructions). SepMateTM-50 tubes contain an insert that creates a physical barrier between the density gradient medium and blood, therefore eliminating the need for carefully layering blood over density gradient medium and reducing the total isolation time. SepMateTM-15 tubes can also be used if fewer PBMCs are required. Other isolation methods such as EasySepTM Direct Human PBMC Isolation Kit can also be used. Prepare PBS + 2% FBS without calcium or magnesium for diluting whole blood. Obtain whole blood collected in anticoagulant-containing tubes such as BD Vacutainer® EDTA tubes. Add 15 mL density gradient medium Ficoll to the 50 mL SepMateTM tube by carefully pipetting it through the central hole of the SepMateTM insert. Dilute whole blood with an equal volume of PBS + 2% FBS and mix the sample gently. For example, dilute 5 mL of whole blood with 5 mL of PBS + 2% FBS. Add the diluted blood on top of the Ficoll layer by pipetting down the side of the SepMateTM tube to preserve the gradient. CRITICAL: No more than 17 mL of diluted blood should be added per SepMateTM capacity. Centrifuge at 1200 × g for 10 min at room temperature (20°C–22°C), with the brake on. Collect the top layer containing the enriched PBMCs using a Pipette Aid into a new 50 mL conical tube. Pellet cells by centrifuging at 300 × g for 8 min. Wash the enriched PBMCs with PBS + 2% FBS twice by centrifuging at 300 × g for 8 min. Ammonium chloride–based lysis buffer can be added to the cell pellet prior to washes to remove red blood cells based on the optimal input for downstream applications. For example, dilute the 10X concentrate BD Pharm LyseTM solution with H2O. Resuspend cell pellet derived from 20 mL blood with 3 mL 1X working solution and incubate at room temperature for 5 minutes followed by two washes. Resuspend cells in a volume of staining buffer to obtain cells at ∼1 × 107 cells/mL for co-staining or flow proxy assay, as detailed below. Approximately 1 million PBMCs can be isolated from 1 mL whole blood. Use this as an approximation to decide the volume of staining buffer. For example, resuspend PBMCs isolated from 5 mL blood into 0.5 mL staining buffer to obtain a concentration of ∼1 × 107 cells/mL.

Designing a flow cytometry panel for cell sorting prior to single-cell CITE-Seq

Isolating a specific cell population of interest using a cell sorter is a common step prior to single-cell CITE-Seq. This allows researchers to exclusively interrogate the cell populations of interest during single-cell sequencing and saves sequencing costs by excluding unwanted cells. Once the protein markers in the sorting panel are decided, successful panel design relies on optimal protein marker-fluorochrome assignment. Key considerations for building the sorting panel include, but are not limited to, instrument configuration, fluorescence spillover, dye brightness, antigen density, and co-expression (Chattopadhyay and Roederer, 2012; Flores-Montero et al., 2019). Evaluating the spread spillover matrix is useful to aid flow cytometry panel design specific to an instrument (Nguyen et al., 2013). Additional panel optimization may be needed to improve upon the initial panel design (Ferrer-Font et al., 2020; Mahnke and Roederer, 2007). Biotinylated primary antibodies, followed by secondary streptavidin-conjugated fluorescent antibodies for cell sorting are compatible with a downstream single-cell CITE-Seq workflow.

Prepare stock solution of flow proxy oligos

Timing: 20 min We designed a flow proxy experiment that allows detection of the antibody-oligonucleotide conjugates (AOC) signal using flow cytometry. First, cells are stained with AOC. Fluorochrome oligonucleotide conjugates as flow proxy oligos containing the complimentary sequence to the AOC oligo are then added. With the binding of flow proxy oligos to AOC, the fluorescent signal is correlated to the AOC signal. The flow proxy experiment is useful for different applications. It is possible to examine the AOC binding or identify the optimal quantity of any AOC reagent for a particular cell type using a flow proxy assay. Compared to using a fluorescent antibody with the same clone, this method allows researchers to titrate the exact lot of the AOC reagent, avoiding the scenario that the same clone of AOC and fluorescent antibody show different phenotypes (Mair et al., 2020). Additionally, identification of the optimal concentration of the AOC reagent will not be affected by the dye brightness of the flow antibody chosen. It is also possible to confirm oligo and antibody conjugation using this assay. In this work, we co-stained cells with fluorescent antibodies and AOC with the same protein marker. With the secondary labeling of the flow proxy oligo, we then evaluated the signal change upon co-staining compared to single staining. We utilized two different flow proxy oligos conjugated to Alexa Fluor™ 647 (AF647). AF647-dT contains 25 thymines (T) and binds to the polyA tail of the BD® AbSeq oligonucleotide (Figure 1). The other flow proxy oligo, the AF647-AbSeq PCR handle, is complementary to the conserved sequence in the 5′ end of the AbSeq oligonucleotide (Figure 1). Using these two flow proxy oligos simultaneously may improve the detection of the AOC signal, based on our experience.
Figure 1

Graphical illustration of the binding between AOC and flow proxy oligos

The AF647-dT flow proxy oligo binds the polyA tail of the oligonucleotide in the AOC reagent, whereas the AF647-AbSeq PCR handle binds the 5′ region of the AOC oligonucleotide. With this secondary labeling, the fluorescence signal on the AF647 channel is correlated to the AOC signal.

Graphical illustration of the binding between AOC and flow proxy oligos The AF647-dT flow proxy oligo binds the polyA tail of the oligonucleotide in the AOC reagent, whereas the AF647-AbSeq PCR handle binds the 5′ region of the AOC oligonucleotide. With this secondary labeling, the fluorescence signal on the AF647 channel is correlated to the AOC signal. According to vendor’s instructions, resuspend the lyophilized flow proxy oligos in DNA suspension buffer to make 100 μM stocks. For this work, the read-out fluorophore for AOCs is always AF647, although other fluorochromes should also work. Here, the fluorescent antibodies are conjugated to various dyes, as derived from an existing multicolor cell sorting panel. Fluorochrome incompatibility of the co-stained sample in the flow proxy assay may arise from imbalanced sizes between fluorescent antibodies and AOC-dye oligo conjugate complexes competing to bind with the cells (Zhang et al., 2017). In that case, changing dyes may be advisable.

Key resources table

CRITICAL: Many reagents such as BD stain buffer and BSB Plus contain sodium azide. Contact with acidic solutions and metal compounds over time may form potentially explosive metal azides. Flush with adequate amounts of water when introducing these materials into a sanitary sewer system. BD, the BD Logo, FACS, FlowJo, Horizon, OptiBuild, Pharm Lyse, Pharmingen, Rhapsody, SeqGeq and Vacutainer are trademarks of Becton, Dickinson and Company or its affiliates. Alexa Fluor is a trademark of Life Technologies Corporation. Cy is a trademark of Global Life Sciences Solutions Germany GmbH or an affiliate doing business as Cytiva. All other trademarks are the property of their respective owners.

Step-by-step method details

Single-cell CITE-Seq can provide great insight to complex biological systems, uncover cellular heterogeneity and reveal novel characteristics (Peterson et al., 2017; Stoeckius et al., 2017). Combining single-cell sorting with single-cell CITE-Seq provides unparalleled resolution to deeply characterize rare cell populations (Mair et al., 2020; See et al., 2018). This protocol was generated to streamline the process of staining cells with flow cytometry antibodies and AOCs. The stained cells can be directly utilized for downstream cell sorting followed by single-cell capture.

Optional step: Flow proxy experiment to evaluate the compatibility for the same protein marker of fluorescent antibody and AOC

Timing: Approximately 2 h When the fluorescent antibody and AOC against the same protein marker are used simultaneously, regardless of the binding epitopes, it is highly recommended to perform a flow proxy experiment to evaluate the compatibility of the two antibodies and the possible signal loss of the co-stained sample compared to the single-stained sample. If there are no overlapping proteins between the fluorescent panel and the AOC panel, move directly to the “co-staining PBMCs with a fluorescent panel and an AOC panel” section. Obtain PBMCs at a concentration of ∼1 × 107 cells/mL. Use 0.5–1 million cells for each sample. It is essential to account for sufficient cells for use in 6 different samples per protein marker. For cells containing myeloid cells and B cells, blocking potential non-specific Fc receptor-mediated false positive signals with human Fc block is recommended: use 5 μL human Fc block for each 100 μL PBMCs. To block more cells, increase the amount of human Fc block proportionally. Incubate cells at room temperature for 10 minutes. Label 6 polystyrene tubes for each protein marker to be tested and add 100 μL PBMCs (0.5–1 million cells/tube) into all 6 tubes. A plate can also be used for cell staining instead of polystyrene tubes. Add the corresponding antibodies to tube 3, 4, 5 and 6 for the first stain (Figure 2).
Figure 2

Graphical illustration of co-staining cells with the same protein marker of fluorescent antibody and AOC

Six tubes need to be prepared and stained with one or two antibodies to examine the possible signal change of the co-stained sample compared to the single stained samples.

Graphical illustration of co-staining cells with the same protein marker of fluorescent antibody and AOC Six tubes need to be prepared and stained with one or two antibodies to examine the possible signal change of the co-stained sample compared to the single stained samples. Antibody quantities used for co-staining antibody quantity used for co-staining with the same clones; for different clones of the same protein marker, use the corresponding optimal amount per test. CRITICAL: Because of the possible competition of the fluorescently labeled antibody with AOC, it is important to add the two antibodies at the same time into the cells for tube 6. Alternatively, cells can be added after adding antibodies to the tubes. For tube 6, if the fluorescent antibody and the AOC are of the same clone, use an equivalent quantity of the two antibodies based on the optimal amount from the vendor’s recommendations. If the optimal amount is different, select one amount to be used for both antibodies (see Figure 3 as an example of identification of optimal antibody amount to use). If the two antibodies are different clones, use the corresponding optimal amount provided by the antibody vendor, which can be different.
Figure 3

An example of co-staining PBMCs with the same CD4 clone and conjugate utilized for surface detection and AOC

PBMCs were co-stained with BUV395 CD4 (clone SK3) and CD4 AOC (clone SK3). Histograms of unstained, single stained, and co-stained samples were overlaid to compare the flow signal (left plot) and AOC signal (right plot). Median fluorescence intensity (MFI) was reduced by approximately half for both fluorescent CD4 surface expression and CD4 AOC signals. The optimal quantity is 0.125 μg for BUV395 CD4 and 0.06 μg for CD4 AOC. 0.125 μg of each antibody was added for co-staining to utilize equal amounts of the two antibodies. 7AAD was used for live/dead cell discrimination.

Pipet mix and incubate the mixture at the room temperature for 30 min. If staining murine cells or delicate human cells, incubation should be performed on ice. Add 2 mL of stain buffer to tube 3, 4, 5 and 6 and centrifuge at 400 × g for 5 min. Aspirate or decant supernatant and gently blot the tube on a lint-free wipe to remove residual liquid from the rim of the tube. Add 2 mL of stain buffer a second time and centrifuge at 400 × g for 5 min. Resuspend tube 3 in 350 μL stain buffer and store at 4°C until flow cytometry acquisition. Resuspend tubes 4, 5 and 6 in 100 μL stain buffer. Dilute 100 μM flow proxy oligos (AF647-dT and AF647-AbSeq PCR handle) using stain buffer to 3.75 μM. Add 1 μL of each of 3.75 μM flow proxy oligos (2 μL in total) into tubes 2, 4, 5 and 6 containing 100 μL cells. Mix by pipetting 10 times. Incubate the cells at room temperature for 20 min, protected from light. Add 2 mL of stain buffer to tubes 1, 2, 4, 5, 6 and resuspend by pipet-mixing. Centrifuge the tube at 400 × g for 5 min. Add 2 mL of stain buffer to each tube a second time and mix the solution. Centrifuge the tube at 400 × g for 5 min. Resuspend cell pellets in 350 μL stain buffer to prepare the 6 tubes for the next step. Samples can be analyzed using any flow cytometry analyzer with appropriate detectors. An example of co-staining PBMCs with CD4 AOC and CD4 fluorescent antibody is shown in Figure 3. Add appropriate amount of live/dead marker to all tubes prior to flow cytometry analysis. Because fluorescent antibodies and flow proxy oligos may non-specifically bind with dead cells, we recommend including a live/dead dye to each tube to gate on live cells during flow cytometry analysis. For example, 7AAD or DAPI can be used. Single-color control tubes need to be prepared for compensation calculation if there is spillover among fluorescent antibody, flow proxy dye and live/dead marker. If no live/dead marker is added, tube 3 and tube 5 can be used for single color compensation controls. An example of co-staining PBMCs with the same CD4 clone and conjugate utilized for surface detection and AOC PBMCs were co-stained with BUV395 CD4 (clone SK3) and CD4 AOC (clone SK3). Histograms of unstained, single stained, and co-stained samples were overlaid to compare the flow signal (left plot) and AOC signal (right plot). Median fluorescence intensity (MFI) was reduced by approximately half for both fluorescent CD4 surface expression and CD4 AOC signals. The optimal quantity is 0.125 μg for BUV395 CD4 and 0.06 μg for CD4 AOC. 0.125 μg of each antibody was added for co-staining to utilize equal amounts of the two antibodies. 7AAD was used for live/dead cell discrimination.

Co-staining PBMCs with a fluorescent panel and an AOC panel

Timing: 1.5 h This protocol describes the procedure of co-staining cells with AOCs and fluorescent antibodies. After staining, cell sorting can be performed directly to enrich cell populations of interest, followed by single-cell CITE-Seq workflow. Obtain the optimal volume per test of all antibodies in both the sorting panel and the AOC panel based on vendor recommendations or flow proxy experiment for the shared protein marker. For example, the optimal volume of BUV395 CD4 (BD Catalog #: 563550) is 5 μL per 1 million cells. The optimal volume of BD® AbSeq AOC reagents is 2 μL for staining 1 million cells. Calculate the total volume of all antibodies to be used in the assay for both the sorting panel and the AOC panel. Subtract the total volume of the two panels from 200 μL to obtain the volume of stain buffer per sample. An example of calculation is in Table 1.
Table 1

An example of co-staining

ReagentVolume/test (1 million cells)
10 plex fluorescent antibody panel50 μL (5 μL × 10 protein markers)
20 plex AOC panel40 μL (2 μL × 20 protein markers)
Cells in stain buffer110 μL
Total volume200 μL

Note: Antibody cocktail volumes can be scaled up based on the number of samples or amount of cells

An example of co-staining Note: Antibody cocktail volumes can be scaled up based on the number of samples or amount of cells when two or more BD Horizon™ Brilliant dyes are present in the sorting panel, Brilliant Stain Buffer (BSB) Plus should be used to mitigate dye to dye interaction and staining artifacts. To stain more than 1 million cells, increase the antibody reagent volume proportionally. Resuspend the PBMCs in the calculated volume of stain buffer in a 5 mL polystyrene tube. Make the fluorescent antibody cocktail and the AOC cocktail separately and place them on ice until cells are ready for staining. If multiple tubes of BD® AbSeq AOCs are used, tubes can be organized in a Latch Rack. Centrifuge the Latch Rack with a plate adaptor at 400 × g for 30 seconds. Open the tubes using an 8-Channel Screw Cap Tube Capper to make the AOC cocktail (Figure 4).
Figure 4

Latch rack for BD® AbSeq Ab-Oligo tubes and 8-channel screw cap tube capper

BD® AbSeq tubes can be organized in the Latch Rack, as shown. The tubes can be opened and closed using the Screw Cap Tube Capper.

Blocking non-specific binding of Fc receptors: add 5 μL of human Fc block per 1 million cells in suspension and incubate cells for 10 min at room temperature. Increase the volume of Fc block appropriately for increasing cell numbers. Combine the two cocktail mixtures and add PBMCs to the antibody cocktail mixtures. Pre-staining cells with the competing antibodies or the antibody that is particularly important for downstream characterization may be a good strategy to preserve the staining resolution. For example, researchers can add the same protein marker present in the AOC panel and the fluorescent panel, if there is any, to the cells first. After 10 minutes of incubation, the two remaining cocktail mixtures can be added. Pipet to mix and incubate for 30–60 min at room temperature. If staining murine cells or delicate human cells, incubation should be performed on ice. Add 2 mL stain buffer to the labeled cells and mix by pipetting. Centrifuge at 400 × g for 5 min. Aspirate or decant supernatant and gently blot the tube on a lint-free wipe to remove residual liquid from the rim of the tube. Repeat the wash for an additional two times by centrifuging at 400 × g for 5 min in between. Resuspend the cell pellet in Pre-Sort buffer for cell sorting. CRITICAL: The co-stained cells can be kept at 4°C in the dark before FACS sorting. However, we highly recommend proceeding to cell sorting as quickly as possible to preserve the cell viability. Latch rack for BD® AbSeq Ab-Oligo tubes and 8-channel screw cap tube capper BD® AbSeq tubes can be organized in the Latch Rack, as shown. The tubes can be opened and closed using the Screw Cap Tube Capper.

Fluorescence-activated cell sorting to isolate cell population of interest

Timing: Approximately 1 h Cell sorting on co-stained cells can be performed using any type of cell sorter. A high level of procedure overview is provided below. Refer to the specific user guide of the instrument used. Start up the cytometer and the computer. Perform quality control of the cell sorter such as running Cytometer Setup and Tracking (CS&T) beads. Prepare the instrument for sorting following specific instrument user guidelines and biosafety regulations (Schmid and Dean, 1997). Visualization of the fluorescent sorting panel using co-stained cells. Run all the single-color controls and calculate the compensation. Run a small portion of the co-stained cells to visualize the fluorescent sorting panel and ensure proper staining. Proceed to sorting the co-stained sample. CRITICAL: To avoid potential transcriptional and proteomic changes and preserve cell viability, keep sorted cells on ice and proceed immediately to downstream single-cell capture (Cossarizza et al., 2019).

Single-cell capture using BD RhapsodyTM single-cell analysis system

Timing: Approximately 2 h A detailed protocol for single-cell capture using the nano-well based BD Rhapsody™ system is described in Erickson et al. (2020) or here. Pause point: The Exonuclease-treated beads can be stored at 2°C–8°C for ≤ 3 months. During the library preparation process, there are multiple stopping points that allow researchers to break down the process into different days if needed.

Expected outcomes

Using the flow proxy experiment described above, we evaluated the compatibility of several protein markers of AOC and fluorescent antibodies with the same specificity for co-staining, including either the same clone or different clones of the two specificities (Figure 5). For protein markers of the same clone, reduction of signal is typically observed for both the fluorescent antibody and AOC due to their competition (Figure 5A). One exception is CD56 AOC, which showed significant reduction of signal intensity (red arrow in Figure 5A), whereas the remaining protein markers showed an acceptable signal loss with co-staining. However, results are more nuanced when using different clones of the same protein marker (Figure 5B). For example, despite signal retention when co-staining using different clones of CD8, suboptimal staining of CCR7 AOC was observed with single staining. Additionally, CD3 AOC and CD19 AOC exhibited drastic signal reduction upon co-staining compared to single AOC staining. We therefore swapped different clones of these three protein markers to utilize the same clone. Signal loss was reduced with co-staining (Figure 5C). Interestingly, when we switched CD56 AOC into a non-competing clone, the AOC signal was restored.
Figure 5

Examples of co-staining PBMCs with the same protein marker of AOC and fluorescent antibody

(A) Co-staining PBMCs with the same clone of AOC and fluorescent antibody. Equivalent amount of the two antibodies were used for co-staining. Reduction of signal was observed for almost all cases at co-staining. Notably, when co-staining PBMCs with the same clone of CD56 PE-Cy7 and CD56 AOC, the signal of AOC was significantly reduced (red arrow) whereas the fluorescent signal remained comparable to the single stained sample. Either 7AAD or DAPI was used as a live/dead cell marker.

(B) Co-staining PBMCs with different clones of the same protein marker of AOC and fluorescent antibody. Diverse results of signal loss were observed during co-staining. 7AAD was used for discriminating dead cells from live cells.

(C) The signal loss was reduced when changing different clones of CCR7, CD3 and CD19 into the same clone. Additionally, changing CD56 AOC from clone B159 to clone NCAM16.2 restored the AOC signal. DAPI was included as a live/dead cell marker. Approximately 1 million PBMCs were used per sample. The percent and MFI of the positive population were labeled in all plots to evaluate signal loss. See Table 2 for antibody concentrations used for co-staining.

Examples of co-staining PBMCs with the same protein marker of AOC and fluorescent antibody (A) Co-staining PBMCs with the same clone of AOC and fluorescent antibody. Equivalent amount of the two antibodies were used for co-staining. Reduction of signal was observed for almost all cases at co-staining. Notably, when co-staining PBMCs with the same clone of CD56 PE-Cy7 and CD56 AOC, the signal of AOC was significantly reduced (red arrow) whereas the fluorescent signal remained comparable to the single stained sample. Either 7AAD or DAPI was used as a live/dead cell marker. (B) Co-staining PBMCs with different clones of the same protein marker of AOC and fluorescent antibody. Diverse results of signal loss were observed during co-staining. 7AAD was used for discriminating dead cells from live cells. (C) The signal loss was reduced when changing different clones of CCR7, CD3 and CD19 into the same clone. Additionally, changing CD56 AOC from clone B159 to clone NCAM16.2 restored the AOC signal. DAPI was included as a live/dead cell marker. Approximately 1 million PBMCs were used per sample. The percent and MFI of the positive population were labeled in all plots to evaluate signal loss. See Table 2 for antibody concentrations used for co-staining.
Table 2

Antibody quantities used for co-staining

Protein markerFluorochromeFlow antibody cloneFlow antibody optimal amount per test (μg)AOC cloneAOC optimal amount per test (μg)
The same clones

CD4BUV395SK30.125aSK30.06
CD11cPEB-ly60.5aB-ly60.5a
CD27BV711M-T2711aM-T2710.25
CD45ROBB515UCHL11aUCHL10.5
HLA-DRAPC-H7G46-61aG46-61a
CD56PE-Cy7B1591aB1590.5
CCR7BV7862-L1-A2a2-L1-A1
CD3BV480UCHT10.75aUCHT10.5
CD19BV421HIB191aHIB190.5
CD90.1BV786HIS510.5aHIS510.5a
CD90.2BV48030-H120.5a30-H120.5a

Different clones

CCR7BV7862-L1-A23D120.5
CD8BV605SK11RPA-T80.25
CD3BV480UCHT10.75SK70.25
CD19BV421HIB191SJ25C10.06
CD56PE-Cy7B1591NCAM16.20.125

antibody quantity used for co-staining with the same clones; for different clones of the same protein marker, use the corresponding optimal amount per test.

Based on the data observed, we generated a decision tree on how to choose the same protein marker of AOC and fluorescent antibody for co-staining (Figure 6). Because results are less predictable when using different clones of two antibodies, we recommend starting from the same clone for co-staining—preferably a clone that you know may work well. Signal for both fluorescent antibody and AOC can be evaluated using the median fluorescence intensity (MFI) in the corresponding channels. By comparing the MFI between the single-stained and co-stained samples, researchers can evaluate the signal loss quantitatively. If researchers are unable to identify the cell population of interest and the percent of positive cells changes (see CD56 AOC signal loss in Figure 5A as an example), seeking non-competing clones for the same protein marker is required. By switching the clone of one antibody, it is possible to restore the signal intensity of either the AOC or the fluorescent antibody, such as CD56 in Figure 5C. However, signal restoration of the two antibodies cannot always be expected. In this regard, researchers need to evaluate the signal loss of the AOC and fluorescent antibody combination on a case-by-case basis and choose a clone from a practical standpoint.
Figure 6

Decision tree for choosing AOC and fluorescent antibodies with the same specificity

We recommend users start from the same clone of the two antibodies and use a flow proxy experiment to evaluate the signal change of co-staining compared to single-staining conditions. If changing into a different clone still shows signal loss in the flow proxy experiment, researchers can choose the best combination of the two antibodies that is most suitable for cell sorting and single-cell CITE-Seq.

Decision tree for choosing AOC and fluorescent antibodies with the same specificity We recommend users start from the same clone of the two antibodies and use a flow proxy experiment to evaluate the signal change of co-staining compared to single-staining conditions. If changing into a different clone still shows signal loss in the flow proxy experiment, researchers can choose the best combination of the two antibodies that is most suitable for cell sorting and single-cell CITE-Seq. Using the decision tree, we identified the optimal amount and clone of CD90.1 and CD90.2 fluorescent antibodies and AOC reagents for co-staining. We performed the comprehensive workflow including co-staining, cell sorting and single-cell CITE-Seq. We could clearly gate on CD90.1 positive and CD90.2 positive cells during cell sorting (Figure 7A) and identify cell subsets characterized by CD90.1 and CD90.2 protein expression in single-cell CITE-Seq (Figure 7B). This supports the protocol presented and the strategy of choosing antibodies for co-staining cells with the same protein marker of AOC and flow antibody.
Figure 7

An example of single-cell CITE-Seq on sorted cells co-stained with the same protein marker of AOCs and fluorescent antibodies

Murine splenocytes were co-stained with a 21-color fluorescent antibody panel and a 34-plex AOC panel containing overlapped protein markers of CD90.1 and CD90.2. The same clones of these two specificities were used and antibody quantities are provided in Table 2.

(A) CD90.1+ cells (pink) and CD90.2+ cells (green) were clearly resolved and sorted during FACS sorting.

(B) Different sorted populations including CD90.1+ and CD90.2+ cells were pooled together and processed for single-cell CITE-Seq using the BD RhapsodyTM single-cell analysis system. Approximately 80% sequencing saturation (∼6500 reads/cell) was achieved for the AOC library. Similar to the flow cytometry data, CD90.1+ and CD90.2+ cell subsets can also be separated using bivariate plot in single-cell CITE-Seq. Additionally, these two populations can be identified via t-distributed stochastic neighbor embedding (tSNE) plots using CD90.1 and CD90.2 protein marker expression.

An example of single-cell CITE-Seq on sorted cells co-stained with the same protein marker of AOCs and fluorescent antibodies Murine splenocytes were co-stained with a 21-color fluorescent antibody panel and a 34-plex AOC panel containing overlapped protein markers of CD90.1 and CD90.2. The same clones of these two specificities were used and antibody quantities are provided in Table 2. (A) CD90.1+ cells (pink) and CD90.2+ cells (green) were clearly resolved and sorted during FACS sorting. (B) Different sorted populations including CD90.1+ and CD90.2+ cells were pooled together and processed for single-cell CITE-Seq using the BD RhapsodyTM single-cell analysis system. Approximately 80% sequencing saturation (∼6500 reads/cell) was achieved for the AOC library. Similar to the flow cytometry data, CD90.1+ and CD90.2+ cell subsets can also be separated using bivariate plot in single-cell CITE-Seq. Additionally, these two populations can be identified via t-distributed stochastic neighbor embedding (tSNE) plots using CD90.1 and CD90.2 protein marker expression.

Limitations

Limitations to choosing antibodies for the overlapping protein marker in the AOC and fluorescent panels

If the signal loss while using the same clone of two antibodies is not acceptable and changing clones of one antibody still shows signal loss, researchers need to evaluate which antibody configuration is best for the downstream applications. If obtaining a strong signal for single-cell CITE-Seq is of top priority, researchers can choose the scenario in which AOC intensity is well preserved at co-staining whereas the fluorescent signal for cell sorting is compromised. If signal resolution for the flow antibody is significantly impacted, researchers may consider changing the dye into a brighter fluorochrome if the sorting panel allows.

Limitations to cell washes post co-staining

Sufficient washing post-AOC staining is important for reducing the noise from unbound AOCs being captured by BD Rhapsody™ system beads during single-cell capture and also help preserve the resolution of fluorescent antibodies. However, each wash results in a certain level of cell loss. Washing AOC-labeled cells 3 times is necessary for reducing the unbound antibodies. Additionally, the process of cell sorting replenishes the buffer where cells reside, which also helps to remove unbound AOCs.

Considerations of optimal cell sorting conditions

The conditions of cell sorting profoundly affect the cell viability of sorted cells (Cossarizza et al., 2019), which is crucial for the data quality of single-cell CITE-Seq. The optimal input cell concentration is critical to ensure that cells are delivered in a consistent concentration to the sorter. Too many cells per second will compromise the purity and yield of sorted cells whereas too few cells per second can increase the sorting time, potentially impacting the quality of sorted cells. Secondly, consider the optimal cell sorting nozzle size to best fit the cell type to be sorted. Thirdly, resuspend the cells to be sorted in an optimal buffer to avoid clumps and preserve cell viability and ensure that the catch buffer is optimized to support the nutrient requirements for the sorted cells. Note that Pre-Sort buffer is well suited for both resuspending cells to be sorted and collecting sorted cells.

Considerations of optimal cell staining workflow

There are two different methods to stain cells for cell sorting followed by single-cell CITE-Seq: co-staining cells with the fluorescent and AOC panels before sorting; or staining sorted cells with AOC panel after sorting. Co-staining may be a better approach in that it saves time by streamlining the workflow and reducing processing time, improving viability and cell resilience. Sorted cells labeled with AOCs can be directly processed for single-cell capture without any additional steps. Additionally, for rare cell populations, washing sorted cells multiple times post-AOC staining, can be detrimental in that the procedure can lead to severe cell loss. In addition, a workflow where staining with a fluorescent antibody followed by cell sorting, and then staining with AOC of the same specificity will have limited success as target antigens are likely bound with fluorescently conjugated antibodies that will block the binding of AOCs and limit their utility for downstream analysis.

Correlation between flow proxy assay results and single-cell CITE-Seq results

The flow proxy experiment is a useful tool to evaluate the protein marker expression level in single-cell CITE-Seq. This is supported by high concordance of cellular composition identified by the two readouts using the same biological sample (Lawlor et al., 2021; Mair et al., 2020). For example, if significant signal loss is observed at co-staining in the flow proxy experiment, researchers need to be cautious when using the antibody combination for cell sorting followed by single-cell CITE-Seq. However, the measurement unit between flow cytometry (median fluorescence intensity) and single-cell CITE-Seq (protein molecule count per cell) is not the same. Additionally, the same antibody clone can yield a different result in a multiomic sequencing experiment relative to flow cytometry (Mair et al., 2020). Hence, the change of fluorescence signal intensity correlated to AOC reagent in the flow proxy assay at co-staining may not be directly translated to the change of protein expression in single-cell CITE-Seq.

Troubleshooting

Problem 1

When adding the live/dead marker 7AAD into the AOC-stained cells, the 7AAD negative population shifts slightly in the positive direction, possibly due to the binding of 7AAD with the oligonucleotides in the AOC reagent (step 19 or in the single-cell capture using BD RhapsodyTM single-cell analysis system section).

Potential solution

If the 7AAD negative population shifts to the positive side in the flow proxy experiment, ensure that the correct concentration of flow proxy oligos has been utilized. If the shift takes place during the sorting for co-stained cells, make a less stringent gate for the live cells. If the shift is too significant and interferes with accurately gating on live cells, either titrating 7AAD or utilizing an alternative live/dead marker is recommended. For example, DAPI shows less this type of issue compared to 7AAD.

Problem 2

Compromised resolution of the fluorescent cell sorting panel (Step 35b). For high-parameter fluorescent sorting panels, pre-testing the panel may be needed before executing the co-staining workflow. For fluorescent antibodies that generate non-optimal staining, titrate the reagents and incorporate isotype controls when needed. Use the optimal PMT voltage settings of the instrument (Maecker and Trotter, 2006). Ensure the compensation matrix is calculated accurately using single-stained controls. For low expressed protein markers, single-stained beads may be needed for compensation calculation.

Problem 3

Cell clumping before sorting (after step 31). Be sure to filter co-stained cells prior to cell sorting. Larger nozzle size and resuspending cells using Pre-Sort buffer may be helpful to prevent sorter clogging due to cell aggregation.

Problem 4

Low cell viability prior to single-cell capture (in the single-cell capture using BD RhapsodyTM single-cell analysis system section). This indicates that cells have been stressed during the workflow. Make sure to work swiftly, spin cells properly, pipette cells gently and keep cells on ice as much as possible throughout the workflow. Be sure to monitor cell viability during the workflow. If cell viability drops after single-cell isolation (e.g., tumor dissociation process), optimize the cell preparation protocol if needed. If cell sorting affects cell viability, include a live/dead marker into the sorting panel and seek to optimize the sorting conditions. For example, using polypropylene collection tubes is helpful to prevent cell trapping by the tube wall. Precoating the collection tubes with FBS provides another approach to improve the cell viability of sorted cells.

Problem 5

Unexpected low cell viability of sorted cells measured by BD RhapsodyTM scanner (in the single-cell capture using BD RhapsodyTM single-cell analysis system section). The measurement of cell viability using the BD RhapsodyTM scanner prior to single-cell capture relies on DRAQ7TM, which binds to double-stranded DNA of dead cells. If the sorted cells are also stained with a fluorescent antibody conjugated to an APC dye, due to the similar excitation and emission spectral profile between DRAQ7TM and APC, an overestimation of the dead cell count of the sorted cell population may occur. In that case, researchers may need to count cell viability under a microscope with a hemocytometer using a non-fluorescent live/dead cell marker such as trypan blue.

Resource availability

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Aaron Tyznik (Aaron_J_Tyznik@bd.com).

Materials availability

This study did not generate new unique reagents.
REAGENT or RESOURCESOURCEIDENTIFIER
Antibodies

BD HorizonTM BUV395 Mouse Anti-Human CD4BD BiosciencesCat# 563550; RRID: AB_2738273
BD HorizonTM BB515 Mouse Anti-Human CD45ROBD BiosciencesCat# 564529; RRID: AB_2744408
BD PharmingenTM APC-H7 Mouse Anti-Human HLA-DRBD BiosciencesCat# 561358; RRID: AB_10611876
BD HorizonTM BV711 Mouse Anti-Human CD27BD BiosciencesCat# 564893; RRID: AB_2739003
BD PharmingenTM PE Mouse Anti-Human CD11cBD BiosciencesCat# 555392; RRID: AB_395793
BD HorizonTM BV480 Mouse Anti-Human CD3BD BiosciencesCat# 566105; RRID: AB_2739507
BD HorizonTM BV421 Mouse Anti-Human CD19BD BiosciencesCat# 562440; RRID: AB_11153299
BD HorizonTM BV605 Mouse Anti-Human CD8BD BiosciencesCat# 564116; RRID: AB_2869551
BD HorizonTM BV786 Mouse Anti-Human CCR7BD BiosciencesCat# 566758; RRID: AB_2869852
BD PharmingenTM PE-Cy7 Mouse Anti-Human CD56BD BiosciencesCat# 557747; RRID: AB_396853
BD OptiBuildTM BV786 Mouse Anti-Rat CD90/Mouse CD90.1BD BiosciencesCat# 740916; RRID: AB_2740558
BD OptiBuildTM BV480 Rat Anti-Mouse CD90.2BD BiosciencesCat# 746840; RRID: AB_2744090
BD® AbSeq Oligo Mouse Anti-Human CD4BD BiosciencesCat# 940001; RRID: AB_2875892
BD® AbSeq Oligo Mouse Anti-Human CD45ROBD BiosciencesCat# 940022; RRID: AB_2875913
BD® AbSeq Oligo Mouse Anti-Human HLA-DRBD BiosciencesCat# 940010; RRID: AB_2875901
BD® AbSeq Oligo Mouse Anti-Human CD27BD BiosciencesCat# 940018; RRID: AB_2875909
BD® AbSeq Oligo Mouse Anti-Human CD11cBD BiosciencesCat# 940024; RRID: AB_2875915
BD® AbSeq Oligo Mouse Anti-Human CD3BD BiosciencesCat# 940000; RRID: AB_2875891
BD® AbSeq Oligo Mouse Anti-Human CD3BD BiosciencesCat# 940307; RRID: AB_2876183
BD® AbSeq Oligo Mouse Anti-Human CD19BD BiosciencesCat# 940004; RRID: AB_2875895
BD® AbSeq Oligo Mouse Anti-Human CD19BD BiosciencesCat# 940247; RRID: AB_2876128
BD® AbSeq Oligo Mouse Anti-Human CD8BD BiosciencesCat# 940003; RRID: AB_2875894
BD® AbSeq Oligo Rat Anti-Human CCR7BD BiosciencesCat# 940014; RRID: AB_2875905
BD® AbSeq Oligo Mouse Anti-Human CCR7BD BiosciencesCat# 940394; RRID: AB_2876258
BD® AbSeq Oligo Mouse Anti-Human CD56BD BiosciencesCat# 940380; RRID: AB_2876248
BD® AbSeq Oligo Mouse Anti-Human CD56BD BiosciencesCat# 940007; RRID: AB_2875898
BD® AbSeq Oligo Mouse Anti-Mouse CD90/Mouse CD90.1BD BiosciencesCat# 940148; RRID: AB_2876037
BD® AbSeq Oligo Rat Anti-Mouse CD90.2BD BiosciencesCat# 940344; RRID: AB_2876216

Biological samples

Whole bloodAny supplierN/A

Chemicals, peptides, and recombinant proteins

BD Pharm LyseTM solutionBD BiosciencesCat# 555899
BD Horizon™ Brilliant Stain Buffer (BSB) PlusBD BiosciencesCat# 566385
Cell Culture Phosphate Buffered Saline (1X)CorningCat# 21-040-CV
Fetal Bovine SerumThermo Fisher ScientificCat# 26140079
Ficoll-Paque PLUS (Density Gradient Medium)CytivaCat# 17144003
Cell Stain Buffer (FBS)BD BiosciencesCat# 554656
Human Fc blockBD BiosciencesCat# 564220
Pre-Sort BufferBD BiosciencesCat# 563503
DAPIBD BiosciencesCat# 564907
7AADBD BiosciencesCat# 559925
DNA Suspension BufferTeknovaCat# T0221
Flow proxy oligos: 5′ Alexa Fluor 647-TTTTTTTTTTTTTTTTTTTTTTTTT 3' (AF647-dT) and 5′ Alexa Fluor 647-AGATCGGAAGAGCACACGTCTG 3' (AF647-AbSeq PCR handle)Any supplierN/A

Critical commercial assays

BD RhapsodyTM Targeted mRNA and AbSeq Amplification KitBD BiosciencesCat# 633774
BD RhapsodyTM Immune Response Panel MmBD BiosciencesCat# 633753

Software and algorithms

Seven Bridges (bioinformatic pipeline for processing the raw sequencing data)BD BiosciencesRRID: SCR_008308 https://www.sevenbridges.com/
FlowJo™ v10.7.2 software (analysis and visualization of flow cytometry data)BD BiosciencesRRID: SCR_008520 https://www.flowjo.com/solutions/flowjo
SeqGeq™ v1.6.0 software (analysis and visualization of single-cell CITE-Seq data)BD Bioscienceshttps://www.flowjo.com/solutions/seqgeq

Other

Plastic whole blood tube with K2EDTABDCat# 366643
Falcon 50 mL Conical Centrifuge TubesCorningCat# 352070
Pipet AidAny supplierN/A
SepMateTM-50STEMCELL TechnologiesCat# 85450
Falcon round bottom polystyrene test tubesCorningCat# 352054
Latch Rack for AbSeq Ab-Oligo tubesThermo Fisher ScientificCat# 4900-BR
8-Channel Screw Cap Tube CapperThermo Fisher ScientificCat# 4105MAT
1.5 mL DNA LoBind TubesEppendorfCat# 0030108051
1.5 mL Protein LoBind TubesEppendorfCat# 0030108442
Pipettes (P20, P200, P1000)Major supplierN/A
Low retention filtered pipette tips (20 μL, 200 μL, 1000 μL)Major supplierN/A
Flow cytometry cell analyzerMajor supplierN/A
  15 in total

1.  Flow cytometry controls, instrument setup, and the determination of positivity.

Authors:  Holden T Maecker; Joseph Trotter
Journal:  Cytometry A       Date:  2006-09-01       Impact factor: 4.355

2.  Introduction to the biosafety guidelines for sorting of unfixed cells.

Authors:  I Schmid; P N Dean
Journal:  Cytometry       Date:  1997-06-01

3.  Panel Design and Optimization for High-Dimensional Immunophenotyping Assays Using Spectral Flow Cytometry.

Authors:  Laura Ferrer-Font; Christophe Pellefigues; Johannes U Mayer; Sam J Small; Maria C Jaimes; Kylie M Price
Journal:  Curr Protoc Cytom       Date:  2020-03

4.  Fluorochrome choices for multi-color flow cytometry.

Authors:  Juan Flores-Montero; Tomas Kalina; Alba Corral-Mateos; Luzalba Sanoja-Flores; Martin Pérez-Andrés; Marta Martin-Ayuso; Lukasz Sedek; Katerina Rejlova; Andrea Mayado; Paula Fernández; Vincent van der Velden; Sebastian Bottcher; Jaques J M van Dongen; Alberto Orfao
Journal:  J Immunol Methods       Date:  2019-06-07       Impact factor: 2.303

5.  Multiplexed quantification of proteins and transcripts in single cells.

Authors:  Vanessa M Peterson; Kelvin Xi Zhang; Namit Kumar; Jerelyn Wong; Lixia Li; Douglas C Wilson; Renee Moore; Terrill K McClanahan; Svetlana Sadekova; Joel A Klappenbach
Journal:  Nat Biotechnol       Date:  2017-08-30       Impact factor: 54.908

Review 6.  Cytometry: today's technology and tomorrow's horizons.

Authors:  Pratip K Chattopadhyay; Mario Roederer
Journal:  Methods       Date:  2012-02-25       Impact factor: 3.608

7.  Simultaneous epitope and transcriptome measurement in single cells.

Authors:  Marlon Stoeckius; Christoph Hafemeister; William Stephenson; Brian Houck-Loomis; Pratip K Chattopadhyay; Harold Swerdlow; Rahul Satija; Peter Smibert
Journal:  Nat Methods       Date:  2017-07-31       Impact factor: 28.547

8.  Single Cell Analysis of Blood Mononuclear Cells Stimulated Through Either LPS or Anti-CD3 and Anti-CD28.

Authors:  Nathan Lawlor; Djamel Nehar-Belaid; Jessica D S Grassmann; Marlon Stoeckius; Peter Smibert; Michael L Stitzel; Virginia Pascual; Jacques Banchereau; Adam Williams; Duygu Ucar
Journal:  Front Immunol       Date:  2021-03-17       Impact factor: 8.786

9.  Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition).

Authors:  Andrea Cossarizza; Hyun-Dong Chang; Andreas Radbruch; Andreas Acs; Dieter Adam; Sabine Adam-Klages; William W Agace; Nima Aghaeepour; Mübeccel Akdis; Matthieu Allez; Larissa Nogueira Almeida; Giorgia Alvisi; Graham Anderson; Immanuel Andrä; Francesco Annunziato; Achille Anselmo; Petra Bacher; Cosima T Baldari; Sudipto Bari; Vincenzo Barnaba; Joana Barros-Martins; Luca Battistini; Wolfgang Bauer; Sabine Baumgart; Nicole Baumgarth; Dirk Baumjohann; Bianka Baying; Mary Bebawy; Burkhard Becher; Wolfgang Beisker; Vladimir Benes; Rudi Beyaert; Alfonso Blanco; Dominic A Boardman; Christian Bogdan; Jessica G Borger; Giovanna Borsellino; Philip E Boulais; Jolene A Bradford; Dirk Brenner; Ryan R Brinkman; Anna E S Brooks; Dirk H Busch; Martin Büscher; Timothy P Bushnell; Federica Calzetti; Garth Cameron; Ilenia Cammarata; Xuetao Cao; Susanna L Cardell; Stefano Casola; Marco A Cassatella; Andrea Cavani; Antonio Celada; Lucienne Chatenoud; Pratip K Chattopadhyay; Sue Chow; Eleni Christakou; Luka Čičin-Šain; Mario Clerici; Federico S Colombo; Laura Cook; Anne Cooke; Andrea M Cooper; Alexandra J Corbett; Antonio Cosma; Lorenzo Cosmi; Pierre G Coulie; Ana Cumano; Ljiljana Cvetkovic; Van Duc Dang; Chantip Dang-Heine; Martin S Davey; Derek Davies; Sara De Biasi; Genny Del Zotto; Gelo Victoriano Dela Cruz; Michael Delacher; Silvia Della Bella; Paolo Dellabona; Günnur Deniz; Mark Dessing; James P Di Santo; Andreas Diefenbach; Francesco Dieli; Andreas Dolf; Thomas Dörner; Regine J Dress; Diana Dudziak; Michael Dustin; Charles-Antoine Dutertre; Friederike Ebner; Sidonia B G Eckle; Matthias Edinger; Pascale Eede; Götz R A Ehrhardt; Marcus Eich; Pablo Engel; Britta Engelhardt; Anna Erdei; Charlotte Esser; Bart Everts; Maximilien Evrard; Christine S Falk; Todd A Fehniger; Mar Felipo-Benavent; Helen Ferry; Markus Feuerer; Andrew Filby; Kata Filkor; Simon Fillatreau; Marie Follo; Irmgard Förster; John Foster; Gemma A Foulds; Britta Frehse; Paul S Frenette; Stefan Frischbutter; Wolfgang Fritzsche; David W Galbraith; Anastasia Gangaev; Natalio Garbi; Brice Gaudilliere; Ricardo T Gazzinelli; Jens Geginat; Wilhelm Gerner; Nicholas A Gherardin; Kamran Ghoreschi; Lara Gibellini; Florent Ginhoux; Keisuke Goda; Dale I Godfrey; Christoph Goettlinger; Jose M González-Navajas; Carl S Goodyear; Andrea Gori; Jane L Grogan; Daryl Grummitt; Andreas Grützkau; Claudia Haftmann; Jonas Hahn; Hamida Hammad; Günter Hämmerling; Leo Hansmann; Goran Hansson; Christopher M Harpur; Susanne Hartmann; Andrea Hauser; Anja E Hauser; David L Haviland; David Hedley; Daniela C Hernández; Guadalupe Herrera; Martin Herrmann; Christoph Hess; Thomas Höfer; Petra Hoffmann; Kristin Hogquist; Tristan Holland; Thomas Höllt; Rikard Holmdahl; Pleun Hombrink; Jessica P Houston; Bimba F Hoyer; Bo Huang; Fang-Ping Huang; Johanna E Huber; Jochen Huehn; Michael Hundemer; Christopher A Hunter; William Y K Hwang; Anna Iannone; Florian Ingelfinger; Sabine M Ivison; Hans-Martin Jäck; Peter K Jani; Beatriz Jávega; Stipan Jonjic; Toralf Kaiser; Tomas Kalina; Thomas Kamradt; Stefan H E Kaufmann; Baerbel Keller; Steven L C Ketelaars; Ahad Khalilnezhad; Srijit Khan; Jan Kisielow; Paul Klenerman; Jasmin Knopf; Hui-Fern Koay; Katja Kobow; Jay K Kolls; Wan Ting Kong; Manfred Kopf; Thomas Korn; Katharina Kriegsmann; Hendy Kristyanto; Thomas Kroneis; Andreas Krueger; Jenny Kühne; Christian Kukat; Désirée Kunkel; Heike Kunze-Schumacher; Tomohiro Kurosaki; Christian Kurts; Pia Kvistborg; Immanuel Kwok; Jonathan Landry; Olivier Lantz; Paola Lanuti; Francesca LaRosa; Agnès Lehuen; Salomé LeibundGut-Landmann; Michael D Leipold; Leslie Y T Leung; Megan K Levings; Andreia C Lino; Francesco Liotta; Virginia Litwin; Yanling Liu; Hans-Gustaf Ljunggren; Michael Lohoff; Giovanna Lombardi; Lilly Lopez; Miguel López-Botet; Amy E Lovett-Racke; Erik Lubberts; Herve Luche; Burkhard Ludewig; Enrico Lugli; Sebastian Lunemann; Holden T Maecker; Laura Maggi; Orla Maguire; Florian Mair; Kerstin H Mair; Alberto Mantovani; Rudolf A Manz; Aaron J Marshall; Alicia Martínez-Romero; Glòria Martrus; Ivana Marventano; Wlodzimierz Maslinski; Giuseppe Matarese; Anna Vittoria Mattioli; Christian Maueröder; Alessio Mazzoni; James McCluskey; Mairi McGrath; Helen M McGuire; Iain B McInnes; Henrik E Mei; Fritz Melchers; Susanne Melzer; Dirk Mielenz; Stephen D Miller; Kingston H G Mills; Hans Minderman; Jenny Mjösberg; Jonni Moore; Barry Moran; Lorenzo Moretta; Tim R Mosmann; Susann Müller; Gabriele Multhoff; Luis Enrique Muñoz; Christian Münz; Toshinori Nakayama; Milena Nasi; Katrin Neumann; Lai Guan Ng; Antonia Niedobitek; Sussan Nourshargh; Gabriel Núñez; José-Enrique O'Connor; Aaron Ochel; Anna Oja; Diana Ordonez; Alberto Orfao; Eva Orlowski-Oliver; Wenjun Ouyang; Annette Oxenius; Raghavendra Palankar; Isabel Panse; Kovit Pattanapanyasat; Malte Paulsen; Dinko Pavlinic; Livius Penter; Pärt Peterson; Christian Peth; Jordi Petriz; Federica Piancone; Winfried F Pickl; Silvia Piconese; Marcello Pinti; A Graham Pockley; Malgorzata Justyna Podolska; Zhiyong Poon; Katharina Pracht; Immo Prinz; Carlo E M Pucillo; Sally A Quataert; Linda Quatrini; Kylie M Quinn; Helena Radbruch; Tim R D J Radstake; Susann Rahmig; Hans-Peter Rahn; Bartek Rajwa; Gevitha Ravichandran; Yotam Raz; Jonathan A Rebhahn; Diether Recktenwald; Dorothea Reimer; Caetano Reis e Sousa; Ester B M Remmerswaal; Lisa Richter; Laura G Rico; Andy Riddell; Aja M Rieger; J Paul Robinson; Chiara Romagnani; Anna Rubartelli; Jürgen Ruland; Armin Saalmüller; Yvan Saeys; Takashi Saito; Shimon Sakaguchi; Francisco Sala-de-Oyanguren; Yvonne Samstag; Sharon Sanderson; Inga Sandrock; Angela Santoni; Ramon Bellmàs Sanz; Marina Saresella; Catherine Sautes-Fridman; Birgit Sawitzki; Linda Schadt; Alexander Scheffold; Hans U Scherer; Matthias Schiemann; Frank A Schildberg; Esther Schimisky; Andreas Schlitzer; Josephine Schlosser; Stephan Schmid; Steffen Schmitt; Kilian Schober; Daniel Schraivogel; Wolfgang Schuh; Thomas Schüler; Reiner Schulte; Axel Ronald Schulz; Sebastian R Schulz; Cristiano Scottá; Daniel Scott-Algara; David P Sester; T Vincent Shankey; Bruno Silva-Santos; Anna Katharina Simon; Katarzyna M Sitnik; Silvano Sozzani; Daniel E Speiser; Josef Spidlen; Anders Stahlberg; Alan M Stall; Natalie Stanley; Regina Stark; Christina Stehle; Tobit Steinmetz; Hannes Stockinger; Yousuke Takahama; Kiyoshi Takeda; Leonard Tan; Attila Tárnok; Gisa Tiegs; Gergely Toldi; Julia Tornack; Elisabetta Traggiai; Mohamed Trebak; Timothy I M Tree; Joe Trotter; John Trowsdale; Maria Tsoumakidou; Henning Ulrich; Sophia Urbanczyk; Willem van de Veen; Maries van den Broek; Edwin van der Pol; Sofie Van Gassen; Gert Van Isterdael; René A W van Lier; Marc Veldhoen; Salvador Vento-Asturias; Paulo Vieira; David Voehringer; Hans-Dieter Volk; Anouk von Borstel; Konrad von Volkmann; Ari Waisman; Rachael V Walker; Paul K Wallace; Sa A Wang; Xin M Wang; Michael D Ward; Kirsten A Ward-Hartstonge; Klaus Warnatz; Gary Warnes; Sarah Warth; Claudia Waskow; James V Watson; Carsten Watzl; Leonie Wegener; Thomas Weisenburger; Annika Wiedemann; Jürgen Wienands; Anneke Wilharm; Robert John Wilkinson; Gerald Willimsky; James B Wing; Rieke Winkelmann; Thomas H Winkler; Oliver F Wirz; Alicia Wong; Peter Wurst; Jennie H M Yang; Juhao Yang; Maria Yazdanbakhsh; Liping Yu; Alice Yue; Hanlin Zhang; Yi Zhao; Susanne Maria Ziegler; Christina Zielinski; Jakob Zimmermann; Arturo Zychlinsky
Journal:  Eur J Immunol       Date:  2019-10       Impact factor: 6.688

10.  A Targeted Multi-omic Analysis Approach Measures Protein Expression and Low-Abundance Transcripts on the Single-Cell Level.

Authors:  Florian Mair; Jami R Erickson; Valentin Voillet; Yannick Simoni; Timothy Bi; Aaron J Tyznik; Jody Martin; Raphael Gottardo; Evan W Newell; Martin Prlic
Journal:  Cell Rep       Date:  2020-04-07       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.